AMPE - Ampio: Short-Term Triple-Digit Upside From Ampion's Progressing Phase 3 Drug Application
- Ampio Pharmaceuticals, Inc. is a non-revenue producing biopharmaceutical company aiming to develop immunology-based therapies for inflammatory conditions.
- Ampio's pipeline consists of one late-stage therapeutic ("Ampion") across six inflammatory indications. Ampion is a novel biologic drug that regulates immune responses by suppressing inflammatory cytokines (proteins) and activating anti-inflammatory cytokines(tissue repair).
- Ampio is not in the greatest financial shape with cash as of 9m 2020 only reaching $9M on top of a 2021 expected cash burn in excess of ~$15M.
- Ampio's 2021 catalysts should arise in 1H 2021 with expected updates from Ampion for the expanded Phase 1 of COVID+ARDS (inhalable) and for greater influence Ampion's update regarding Phase 3 P2 for OAK under the FDA's SPA.
- In summary, the author projects Ampio Pharmaceuticals, Inc. as a "buy" at a 3-5 year price target of $9.2 (+309% upside).
For further details see:
Ampio: Short-Term Triple-Digit Upside From Ampion's Progressing Phase 3 Drug Application